Theravance Biopharma annual debt-to-equity ratio
2017
2022
2023
2024
2025
Theravance Biopharma Debt-to-Equity Ratio Growth & History (TBPH)
Theravance Biopharma's debt-to-equity ratio was 0.14 for fiscal 2025.
View full Theravance Biopharma company overviewTheravance Biopharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.14 | −0.14 | −49.29% |
| 2024 | 2024-12-31 | 0.28 | 0.05 | +22.97% |
| 2023 | 2023-12-31 | 0.23 | 0.11 | +95.49% |
| 2022 | 2022-12-31 | 0.12 | — | — |
| 2017 | 2017-12-31 | 1.94 | — | — |
Theravance Biopharma quarterly debt-to-equity ratio
Q4.17
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.13 | −0.07 | −35.57% |
| Q1 2026 | 2026-03-31 | 0.14 | −0.15 | −51.96% |
| Q4 2025 | 2025-12-31 | 0.14 | −0.14 | −49.29% |
| Q3 2025 | 2025-09-30 | 0.19 | −0.05 | −20.90% |
| Q2 2025 | 2025-06-30 | 0.21 | −0.03 | −14.23% |
| Q1 2025 | 2025-03-31 | 0.29 | 0.06 | +24.08% |
| Q4 2024 | 2024-12-31 | 0.28 | 0.05 | +22.97% |
| Q3 2024 | 2024-09-30 | 0.24 | 0.04 | +17.32% |
| Q2 2024 | 2024-06-30 | 0.24 | 0.06 | +30.59% |
| Q1 2024 | 2024-03-31 | 0.23 | 0.10 | +69.25% |
| Q4 2023 | 2023-12-31 | 0.23 | 0.11 | +95.49% |
| Q3 2023 | 2023-09-30 | 0.21 | 0.10 | +90.60% |
| Q2 2023 | 2023-06-30 | 0.18 | — | — |
| Q1 2023 | 2023-03-31 | 0.14 | — | — |
| Q4 2022 | 2022-12-31 | 0.12 | — | — |
| Q3 2022 | 2022-09-30 | 0.11 | — | — |
| Q4 2017 | 2017-12-31 | 1.94 | — | — |
Theravance Biopharma debt-to-equity ratio trends
Between the periods ended 2017-12-31 and 2025-12-31, Theravance Biopharma's debt-to-equity ratio decreased from 1.94 to 0.14, a change of −1.80. The latest reported quarter, Q2 2026, shows 0.13.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Theravance Biopharma source filings ↗